1,118 results on '"Mitsiades, Constantine S."'
Search Results
2. KDM6A regulates immune response genes in multiple myeloma
3. NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome
4. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
5. Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
6. Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
7. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
8. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
9. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
10. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
11. Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein
12. Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line
13. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
14. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
15. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
16. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
17. Transcriptional Signature of Histone Deacetylase Inhibition in Multiple Myeloma: Biological and Clinical Implications
18. Molecular Sequelae of Proteasome Inhibition in Human Multiple Myeloma Cells
19. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions
20. Abstract 667: Single-cell functional genomics of natural killer cell evasion by tumor cells
21. Table S1 from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
22. Data from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
23. Supplementary Figures 1 - 10 from Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
24. Figure S1 - Figure S8 from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
25. Supplementary Figure Legend from Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
26. Data from Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
27. Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
28. Data from The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
29. Data from Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
30. Supplementary Data from The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
31. Supplementary Figure Legends from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
32. Supplementary Data from Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib
33. Supplementary Figure 2 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
34. Supplementary Figure 3 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
35. Supplementary Figure 1 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
36. Supplementary Figure 4 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
37. Supplementary Data from Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias
38. Supplementary Figure 6 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
39. Supplementary Data from Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment
40. Data from Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment
41. Supplementary Figure 5 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
42. Supplementary Figure 8 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
43. Supplementary Figure 3b from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
44. Supplementary Figures 1-7 from Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
45. Supplementary Table 1 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
46. Supplementary Methods, Figure Legends 1-8 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
47. Supplementary Figure 2 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
48. Supplementary Figure 5 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
49. Supplementary Figure 6 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
50. Supplementary Figure 4 from Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.